Cargando…

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride

Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride (AMR) is a synthetic anthracycline anticancer agent a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, Tatsuo, Kudoh, Shinzoh, Hirata, Kazuto
Formato:	Texto
Lenguaje:	English
Publicado:	Libertas Academica 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076041/ https://www.ncbi.nlm.nih.gov/pubmed/21499556 http://dx.doi.org/10.4137/CMO.S5072

Ejemplares similares

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer
por: Ogawara, Daiki, et al.
Publicado: (2010)

C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin
por: Nagata, Misato, et al.
Publicado: (2013)

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
por: Horita, Nobuyuki, et al.
Publicado: (2016)

Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs
por: Umekawa, Kanako, et al.
Publicado: (2013)

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
por: Suzumura, Tomohiro, et al.
Publicado: (2012)

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)

Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study
por: Uda, Sayaka, et al.
Publicado: (2022)

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
por: Yamamoto, Michiko, et al.
Publicado: (2009)

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017)

Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study
por: Sone, Hideyuki, et al.
Publicado: (2018)

Efficacy of weekly amrubicin for refractory or relapsed non-small cell lung cancer: A protocol of systematic review and meta-analysis
por: Dang, Dong, et al.
Publicado: (2020)

Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study
por: Oka, Takako, et al.
Publicado: (2014)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
por: Ding, Qian, et al.
Publicado: (2013)

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2020)

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
por: Kushiro, Kohei, et al.
Publicado: (2022)

Incremental low doses of amrubicin for the treatment of bone marrow metastasis in small cell lung cancer
por: Asai, Nobuhiro, et al.
Publicado: (2013)

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer
por: Sekine, Ikuo, et al.
Publicado: (2016)

Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2023)

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute
por: Sonehara, Kei, et al.
Publicado: (2019)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lung cancer: a meta-analysis
por: Wu, Ji-Feng, et al.
Publicado: (2019)

Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the Liver
por: Isobe, Taichi, et al.
Publicado: (2009)

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
por: Akamatsu, Hiroaki, et al.
Publicado: (2021)

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
por: Makino, Yoshinori, et al.
Publicado: (2019)

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)
por: Uematsu, Shinya, et al.
Publicado: (2022)

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
por: Sun, Yan, et al.
Publicado: (2016)

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status
por: Igawa, Satoshi, et al.
Publicado: (2018)

Long-term Survival of a Patient with Small Cell Lung Cancer Secreting ADH and ACTH Simultaneously, Following the Prolonged Use of Amrubicin
por: Kosuda, Aya, et al.
Publicado: (2019)

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots
por: Imamura, Fumio, et al.
Publicado: (2015)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
por: Ryuge, Shinichiro, et al.
Publicado: (2009)

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer
por: Masuda, Noriyuki, et al.
Publicado: (2010)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma
por: Sakaida, Emiko, et al.
Publicado: (2017)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Tumor‐selective Distribution of an Active Metabolite of the 9‐Aminoanthracycline Amrubicin
por: Noguchi, Toshihiro, et al.
Publicado: (1998)

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study
por: Akagi, Kazumasa, et al.
Publicado: (2022)

Amrubicin is effective against small cell carcinoma of the prostate as a second‐line chemotherapeutic agent: A case report
por: Maesaka, Fumisato, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ik3omlbih98dkpj02rg9bdcnfl